

Zolgensma® (Onasemnogene Apeparvovec-xioi) Prior Authorization Form

Member Name: _____ **Date of Birth:** _____ **Member ID#:** _____

Drug Information

Physician billing (HCPCS code: _____) Pharmacy billing* (NDC: _____)
*The NDC for this weight-based medication is specific to the dose required. The NDC provided should reflect the member's current weight.
Projected Date of Infusion: _____ **Dose:** _____ **Regimen:** _____

Zolgensma® Billing Provider Information

Provider NPI: _____ **Provider Name:** _____

Provider Phone: _____ **Provider Fax:** _____

Name of outpatient health care facility where Zolgensma® will be delivered to and administered at: _____

Prescriber Information

Prescriber NPI: _____ **Prescriber Name:** _____

Prescriber Phone: _____ **Prescriber Fax:** _____ **Specialty:** _____

Criteria

For Authorization (Only one Zolgensma® infusion will be approved per member per lifetime):

1. If not previously submitted, please provide the **member's recent progress notes discussing respiratory status.**
2. What is the diagnosis for which the medication is being prescribed?
 - Spinal muscular atrophy (SMA)
 - A. Has the diagnosis been confirmed by molecular genetic testing? Yes ___ No ___
 - B. Does member have bi-allelic pathogenic variants in the *survival motor neuron gene 1 (SMN1)*?
Yes ___ No ___
 - Other, please list: _____
3. Will member have reached full-term gestational age prior to the "Projected Date of Infusion" provided in the Drug Information section of this form? Yes ___ No ___
4. Is member currently dependent on permanent invasive ventilation? Yes ___ No ___
If member requires ventilator support, please provide a recent nursing note stating hours on the ventilator per day.
 - A. If member is currently dependent on permanent ventilation, please specify number of hours per day member requires ventilator support: _____
 - B. If member is currently dependent on permanent ventilation, how many continuous days has member required ventilator support: _____
 - C. Has the member required ventilator support in the absence of an acute, reversible illness or a perioperative state? Yes ___ No ___
5. Is Zolgensma® being prescribed by a neurologist, specialist with expertise in treatment of SMA, or an advanced care practitioner with a supervising physician who is a neurologist or specialist with expertise in treatment of SMA? Yes ___ No ___
6. Please provide member's baseline anti-AAV9 antibody titers: _____
7. Does prescriber agree to monitor liver function tests, platelet counts, and troponin-I at baseline and as directed by the Zolgensma® prescribing information? Yes ___ No ___
8. Does prescriber agree to administer systemic corticosteroids starting 1 day prior to the Zolgensma® infusion and continue as recommended in the prescribing information based on member's liver function? Yes ___ No ___
9. Will the facility where Zolgensma® will be delivered to and administered at, and pharmacy if applicable, adhere to the storage and handling requirements in the Zolgensma® prescribing information? Yes ___ No ___
10. Is member currently receiving treatment with Spinraza® (nusinersen)? Yes ___ No ___
11. Is member currently receiving treatment with Evrysdi™ (risdiplam)? Yes ___ No ___
12. Will Spinraza® or Evrysdi™ treatment be used concomitantly with Zolgensma®? Yes ___ No ___
13. Please provide member's current weight: _____ Date taken: _____

Prescriber Signature: _____ **Date:** _____

(By signature, the physician confirms the criteria information above is accurate and verifiable in patient records.) **Specific information/documentation will be requested if necessary. Failure to complete this form in full will result in processing delays.**

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.